Adults in the UK living with advanced biliary tract cancer now have a new treatment option after the Medicines and Healthcare products Regulatory Agency (MHRA) approved zanidatamab, also known as Ziihera, on 19 February 2026.
The decision marks an important development for patients whose cancer shows high levels of the HER2 protein and has progressed despite previous treatment. The medicine is intended for cases where the cancer cannot be removed through surgery and has spread to nearby tissues or other parts of the body.
Biliary tract cancer, which affects the bile ducts and related structures, is rare but often aggressive. For many patients, especially those diagnosed at a later stage, treatment options have historically been limited once the disease advances. Targeted therapies like zanidatamab signal a shift towards more personalised cancer care, focusing on specific biological markers such as HER2.
Zanidatamab is given through an intravenous infusion every two weeks. In a clinical study involving 80 patients with locally advanced or metastatic biliary tract cancer that could not be surgically removed, researchers found encouraging results among those with high HER2 levels. Of the 62 patients in this subgroup, around 52 percent experienced tumour shrinkage or had no detectable cancer after an average follow-up of 34 months.
While the study did not compare Ziihera directly against a placebo or another cancer medicine, the response rate provides meaningful hope in an area where new treatment options are urgently needed.
Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said the approval reflects the regulator’s commitment to ensuring patients can access safe and effective medicines where there is an unmet clinical need. He confirmed that, as with all approved medicines, the agency will continue to monitor the safety and effectiveness of zanidatamab as its use expands.
The approval was granted to Jazz Pharmaceuticals Research UK Limited through the International Recognition Procedure, which allows the UK to draw on trusted international regulatory decisions to help bring promising treatments to patients more quickly.
For diaspora communities across the UK, breakthroughs like this carry particular significance. In many households, cancer diagnoses affect not just individuals but entire families, with relatives both in Britain and overseas closely following treatment developments. Some communities face disparities in early diagnosis and access to specialist care, making new targeted therapies even more important.
Health awareness within diaspora groups has grown significantly in recent years, with more families seeking information about genetic markers, clinical trials and innovative treatments. The approval of zanidatamab reinforces the UK’s role as a country where patients can access advanced oncology medicines without unnecessary delay.
Search interest around HER2-positive cancers, targeted cancer drugs and new UK cancer approvals remains strong, especially when patients are seeking the latest options after standard therapies fail. Clear information about who qualifies for treatment, how it is administered and what the clinical data shows helps patients and caregivers make informed decisions in consultation with healthcare professionals.
As with any medicine, zanidatamab comes with potential side effects and restrictions. Patients are advised to consult the official package leaflet and speak with their oncology team to understand whether the treatment is suitable for their individual case. Full prescribing details and patient information will be published on the MHRA website within seven days of approval.
At Chijos News, we recognise that medical breakthroughs are not just policy announcements. They are moments of hope for families navigating life-altering diagnoses. As the UK continues to approve innovative treatments for rare and advanced cancers, we remain committed to informing diaspora communities about developments that could shape their health and future.